Detalhe da pesquisa
1.
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Am J Hematol
; 95(6): 604-611, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32096887
2.
MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.
Am J Hematol
; 93(1): 100-106, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29047144
3.
TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Br J Haematol
; 174(2): 218-26, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27061303
4.
Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia.
Blood Cells Mol Dis
; 73: 45-46, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249383
5.
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Blood Coagul Fibrinolysis
; 26(7): 743-9, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25811447
6.
Assessment of changes in membrane properties of platelets from patients with chronic myeloid leukaemia in different stages of the disease.
Blood Coagul Fibrinolysis
; 25(2): 142-50, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24346354